Systemic lupus erythematosus (SLE) is an intricate autoimmune disease characterized by its impact on various organ systems, presenting with a wide range of clinical manifestations such as hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, immunologic, cardiac, pleuropulmonary, and renal symptoms. Although its etiology is primarily autoimmune, various triggers, such as pregnancy, certain drugs, and infections, can result in "flares" with frequent relapses. Although more common in females, SLE is not uncommon in males, with a significant proportion experiencing a high disease burden. Over the years, many treatment modalities and approaches in modern medicine have evolved to combat this disease. However, it still poses a challenge to treating physicians due to the intricate elements in its pathogenesis. Further evidence-based studies are necessary to enhance our understanding of the disease. We describe the case of a 53-year-old man who presented with a three-day history of fever and a one-day history of altered sensorium. On evaluation, he was found to have pancytopenia and acute kidney injury. He was worked up for infectious and inflammatory causes. Investigations were strongly in favor of SLE and aseptic meningitis. We started him on pulse steroid therapy, following which he had substantial recovery. After one year, he presented with complaints of frothy urine, when lupus nephritis was diagnosed, and he was started on specific immunosuppressive agents. He has had no further episodes of relapse since then.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522842 | PMC |
http://dx.doi.org/10.7759/cureus.70484 | DOI Listing |
Lupus
December 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Background: Patients with cutaneous lupus erythematosus (CLE) can present with one or multiple different subtypes of CLE. There is limited understanding of the prevalence and associated risk factors for having multiple CLE subtype diagnoses.
Objective: This study characterized the frequency and risk factors for having multiple CLE subtypes.
Eur J Immunol
December 2024
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Cell Biol Toxicol
December 2024
Department of Rheumatology and Immunology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
The autoimmune disorder known as Systemic Lupus Erythematosus (SLE) exhibits intricate features with abnormal immune responses leading to tissue injury. The generation of antibodies and the disruption of immune regulation heavily depend on the pivotal function of T follicular helper (Tfh) cells. Iron dysregulation is significant in autoimmune diseases, impacting immune cell function and disease progression.
View Article and Find Full Text PDFClin Appl Thromb Hemost
December 2024
Department of Blood Transfusion, The Central Hospital of Shaoyang, Shaoyang, China.
The Knops blood group system is an independent blood group system recognized by International Society of Blood Transfusion (ISBT) in 1992, and latest time consisting of 13 antigens carried on a glycoprotein of 2489 amino acids and called the Complement C3b/C4b Receptor 1 (CR1). Erythrocyte KN antigen was first reported in 1970, and CR1 is a protein coding gene that is a member of the receptors of complement activation (RCA) family and is located in the "cluster RCA" region of chromosome 1. CR1 is an important participant in the erythrocyte immune machinery and plays an major role in inhibiting complement activation, and polymorphisms in its expression have been closely associated with a variety of diseases, including systemic lupus erythematosus (SLE), malaria, Plasmodium falciparum malaria, Alzheimer's disease (AD) and leprosy.
View Article and Find Full Text PDFNephrol Dial Transplant
December 2024
Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.
This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients. LN significantly increases the risk of mortality and progression to end-stage kidney disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!